N -acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial

Table 3 Primary and secondary end-points after coronary angiography^a

	NAC group(n = 45)	Placebo group(n = 45^b)	P value
Primary end-point
Incidence of CIN, n(%)	5(11.1%)	6(14.3%)	0.656
Secondary end-points
Change in serum creatinine, mg/dL	-0.016 ± 0.363	-0.018 ± 0.467	0.975
Change in serum urea nitrogen, mg/dL	-1.73 ± 24.03	-3.71 ± 24.26	0.703
Change in creatinine clearance, mL/min	2.86 ± 8.84	3.78 ± 10.87	0.676

^a All plus-minus values are mean ± SD. CIN, contrast-induced nephropathy.
^bWhile 45 patients were enrolled in each group, serum creatinine and urea nitrogen measurements were not available for 3 placebo patients who were discharged immediately after coronary angiography and did not return for subsequent blood sampling (comparison, 45 NAC patients vs. 42 placebo patients).